metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Intrahepatic Cholestasis Induced by Leflunomide: An Unusual Presentation of DILI
Información de la revista
Vol. 29. Núm. S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(febrero 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 29. Núm. S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(febrero 2024)
Acceso a texto completo
Intrahepatic Cholestasis Induced by Leflunomide: An Unusual Presentation of DILI
Visitas
337
Genesis P. Martínez-Pérez, Pamela Duran-Azamar, Ana D. Cano-Contreras, Peter Grube-Pagola, José M. Remes-Troche
Institute of Medical-Biological Research, Veracruzana University, Mexico
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Figuras (2)
Tablas (1)
Table 1. Control of laboratory studies
Suplemento especial
Este artículo forma parte de:
Vol. 29. Núm S2

Abstracts Asociación Mexicana del Hígado (AMH) 2023

Más datos
Introduction and Objectives

Leflunomide is a drug used to treat autoimmune diseases. However, despite its therapeutic benefits, adverse effects have been reported after six months of treatment, including liver damage.

Materials and Patients

A 19-year-old female from Acayucan, Veracruz, without significant hereditary or family history, drug addiction denied, with a pathological history of hypothyroidism for 2 years and rheumatoid arthritis since the age of 15, treated with leflunomide 20 mg, chloroquine 150 mg, levothyroxine 100 mcg. She presented in October 2022 with nausea, vomiting, postprandial abdominal pain, jaundice. Abdominal ultrasound revealed chronic calculous cholecystitis. Laparoscopic cholecystectomy was performed in December 2022 without complications. After surgical treatment, he persisted with jaundice, alteration of liver function tests of mixed pattern that evolves to cholestatic pattern (R factor 0.2, see Table 1). Non-reactive to viral hepatitis A, B and C, HIV, negative antibodies ANA, AML, AMA, anti-DNAds, anti-Smith, anti-Rho, complement C3 145 and C4 33. Cholangiography, with hepatomegaly, diffuse hepatic steatosis without evidence of biliary lesions. Liver biopsy showed features of portal and lobular hepatitis, intracytoplasmic and intracanalicular cholestasis, macrovesicular steatosis, and F2 fibrosis according to METAVIR (Fig. 1), which were not consistent with autoimmune or viral disease. RUCAM score with possible relation to hepatoxicity (4 points), so it is considered drug-induced liver injury (leflunomide).

Results

Leflunomide was discontinued and treatment was adjusted to chloroquine 150 mg and prednisone 50 mg. Clinical and biochemical improvement was observed.

Conclusions

This case highlights the importance of suspecting DILI in patients treated with potentially hepatotoxic drugs and with alterations in liver biochemistry. It is a rare disease for which there are no specific markers. Therefore, liver biopsy is a useful tool for early diagnosis.

Texto completo

Ethical statement

The identity of the patients is protected. Consentment was obtained.

Declaration of interests

None

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Figure 1. Liver tissue with widened portal spaces, mild inflammatory portal infiltrate, thick droplet steatosis, intracytoplasmic and ductal cholestasis.

Table 1.

Control of laboratory studies

PARAMETER  11-Feb  23-Feb  23-Mar  21-Apr  24-May  5-Jul 
Total bilirubin (mg/dL)  3.8  4.1  8.61  14.5  8.15  0.76 
Direct bilirubin (mg/dL)  2.47  3.3  6.64  7.81  0.34 
Indirect bilirubin (mg/dL)  1.33  0.8  1.97  6.77  0.42 
AST (U/L)  65  95  277  236  168  48 
ALT (U/L)  18  29  41  64  101  50 
Alkaline phosphatase (U/L)  253  142  569  217  146  132 
GGT (U/L)  245  413  322  702  607  154 
TG (mg/dL)  803  411  225  155 
Cholesterol (mg/dL)  324  289  296  194 

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos